No abstract available.

No abstract available.
Adult* ; Humans ; Life Style*

No abstract available.
Anticoagulants* ; Venous Thromboembolism*

No abstract available.
Protein Kinases

Venous thrombosis in atypical locations means thrombosis of upper extremity deep vein, cerebral venous sinus, splanchnic vein including portal, hepatic, mesenteric and splenic vein, renal vein, ovarian vein and retinal vein. This thrombosis rarely occurred and could be affected by the involved organ when compared to the incidence and cause of deep vein thrombosis in lower extremity with or without pulmonary embolism. There is a limitation to perform a large-scaled randomized trial for these rare conditions, and several recommendations based on results of small-sized studies and observational registries are available now. Therefore, we need multi-department and international collaboration to test the efficacy and safety of anticoagulation including new oral anticoagulants in the treatment of venous thrombosis in atypical locations.
Anticoagulants ; Budd-Chiari Syndrome ; Cerebral Veins ; Cooperative Behavior ; Incidence ; Lower Extremity ; Pulmonary Embolism ; Registries ; Renal Veins ; Retinal Vein ; Splenic Vein ; Thrombosis ; Upper Extremity ; Upper Extremity Deep Vein Thrombosis ; Veins ; Venous Thrombosis*

The nationwide statistical analysis of each disease of classical myeloproliferative neoplasm (MPN) in Korea has not been reported yet. To this end, we have analyzed incidence rates, survival rates and treatment pattern of polycythemia vera (PV), primary myelofibrosis (MF) and essential thrombocythemia (ET) using Korea National Cancer Incidence Database (KNCIDB) and Health Insurance Review and Assessment Service (HIRA) database. Between 2003 and 2011, a total of 4,342 new cases of MPN were reported to the KNCIDB. ET was the most common, followed by MF and PV. The crude incidence rates for PV, MF, and ET have increased during the period, reaching 0.40, 0.15, and 0.84 per 100,000, respectively. Five-year relative survival rate of all MPN patients was 89.3%, with lowest relative survival rate with MF (53.1%). The prevalence of each disease estimated from HIRA data also increased during the study period. Notably, ET was found to be most prevalent. The prescription rate of hydroxyurea and phlebotomy to PV, MF and ET patients remained constant over the period, and the prescription rate of hydroxyurea was higher in patients with age over 60 years. This is the first Korean nationwide statistics of MPN, using central registry data. This set of data can be utilized to compare the Korean MPN status to international data and guidelines.
Humans ; Hydroxyurea ; Incidence* ; Insurance, Health ; Korea* ; Phlebotomy ; Polycythemia Vera ; Prescriptions ; Prevalence* ; Primary Myelofibrosis ; Survival Rate ; Thrombocythemia, Essential

No abstract available.
Diagnosis* ; Humans ; Venous Thromboembolism*

No abstract available.
Diagnosis* ; Humans ; Venous Thromboembolism*

No abstract available.
Phenytoin* ; Stevens-Johnson Syndrome*

Multiple myeloma is a hematologic neoplasm with a unique and characteristic manifestation. This condition is responsible for 10% of hematologic malignancies, and thus represents 1% of all cases of cancer in the US. In Korea, unlike in Western society, myeloma has classically been relatively rare, due in part to racial differences. However, the incidence of this disease in Korea has increased steadily over the last 25 years. During this period, both the incidence of and mortality due to myeloma increased by up to 30-fold. Currently, incidence rate and mortality rate exceed 1.0/100,000. Possible reasons for this increase include better detection, as well as an actual increase, probably attributable to contributing factors, including pollution, exposure to chemicals, and socioeconomic change, all of which are related to rapid industrialization. Aging is another important factor contributing to this perceived increase. With the advent of targeted therapy, Korean myeloma study group was organized under the auspice of Korean society of hematology. In addition, Korean myeloma registry was established recently. In this study, epidemiological changes in the incidence and mortality of multiple myeloma in Korea are assessed and compared with the situations of the US and Japan. This article also claims the need for multicenter clinical trials as well as activation of basic researches in myeloma.
Aging ; Epidemiologic Studies ; Epidemiology ; Hematologic Neoplasms ; Hematology ; Incidence ; Japan ; Korea* ; Mortality ; Multiple Myeloma* ; Prevalence ; Industrial Development